Diagnosis to treatment in days, not weeks

NCCN guidelines recommend that all Stage IV NSCLC patients be tested for potential DNA and RNA biomarkers that would open the door to targeted therapeutic options.  

However, fewer than 50% of patients undergo comprehensive biomarker testing in the US.1

Why? Because unfortunately the current industry standard for comprehensive biomarker testing - next-generation sequencing (NGS) - has multiple limitations that have significantly impacted your ability to routinely utilize biomarker testing:

  • Time to receive test results - Can take weeks to receive test results.2  
  • Insufficient sample quantity – 25% of lung samples do not contain sufficient DNA material to qualify for testing.3   
  • Quality Control (QC) failure rate - Complexity of testing process often yields no results.3 
  • DNA only testing - Potentially missing actionable RNA fusions.4
  • Actionability – Test reports contain pages of non-actionable information.

ASPYRE-Lung overcomes these barriers - Positioning it as the ideal first choice when you need to rapidly identify the best treatment options for your patients.

Fast time to treatment

ASPYRE® is a patented molecular chemistry that uses a unique enzymatic reaction to dramatically accelerate the detection of actionable biomarkers from blood or tissue within hours vs. weeks for sequencing technologies  


ASPYRE is as sensitive and specific as gold standard NGS assays, with 100% positive and negative percent agreement demonstrated across both DNA & RNA. 

Actionable results

ASPYRE’s comprehensive lung panel identifies all NCCN guideline recommended biomarkers for NSCLC patients, with an easy to interpret two-page report.

Reduced sample requirements

ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, compared to 20% or 30% for most competing assays, minimizing the frustration associated with QNS rates  


ASPYRE simultaneously analyzes DNA and RNA from blood or tissue in a single assay, maximizing the opportunity to identify mutations and fusions, while avoiding the additional time and expense of running separate assays.



  1. Biomarker tissue journey among patients with untreated metastatic non-small cell lung cancer (MNSCLC) in the U.S. Oncology Network community practices. (Oral Abstract Session, ASCO 2021), Robert NJ, et al. J Clin Oncol.2021;39;(suppl 15; abstr 9004). Doi:10.1200/JCO.20211.39.15_suppl.9004 
  2. Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A retrospective Analysis of Real-World Data, DOI: 10.1200/OP.22.00611 JCO Oncology Practice, published online August 09, 2023 
  3. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer, Helen Sadik, PhD. 
  4. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden, Ryma Benayed, et. Al., Clin Cancer Res (2019) 25 (15): 4712-4722. 


Straightforward physician report

Sample Report 4@2x

Featured resources & publications


The ASPYRE technology

Read more about how the unique molecular biology behind ASPYRE overcomes the limitations of PCR and NGS to increase access to comprehensive biomarker testing.


Ultra-sensitive molecular detection of gene fusions from RNA using ASPYRE

Gray et al, BMC Medical Genomics | (2022) 15:215

Single-copy detection of somatic variants from solid and liquid biopsy

A-L. Silva et al, Scientific Reports | (2021) 11:6068


ASPYRE-Lung now available

By simplifying the detection of genomic biomarkers, use of ASPYRE-Lung as a first-line diagnostic helps identify those NSCLC patients who will likely benefit from precision medicine in a fraction of the time and at a fraction of the cost of NGS.

Contact us

Connect with a representative

Contact us and a member of our team will reach out to you.